In summary, this study confirmed that LBP combined with oxaliplatin plays a role in reversing drug resistance in colon cancer cells by down-regulating the PMI/PI3K/AKT pathway and simultaneously inhibiting the expression of ABCG2+ colon cancer stem cells to promote apoptosis. Here, AKT1 is linked to colonic neoplasm.